🚨We have exciting news! Our new facilities at
@CICPhilly will expand our R&D capabilities & accelerate the advancement of our product #pipeline to further our mission of providing #immunotherapies to large patient populations. #celltherapy Read HERE: tinyurl.com/54z397a4
Tevogen Bio
691 posts
Specialty immunotherapy biotech developing off-the-shelf precision #Tcell therapeutics in #oncology, #neurology, and #virology. $TVGN
- How do you make #healthcare both profitable and #affordable? Meet @TevogenBio and its founder - a 2023 #Nobel Peace Prize nominee - who appears to have found an answer. TEVOGEN.COM tbsnews.net/bangladesh/hea…
- Our goal is to provide a meaningful tool in the fight against #COVID19 particularly for high-risk patients who may be susceptible to reduced neutralization activity of vaccine-induced and #monoclonalantibodies conveyed immunity in #OmicronVariant & others. businesswire.com/news/home/2021…
- “I am highly optimistic that TVGN 489 will offer a meaningful solution for both acute and #LongCovid patients,” said Neal Flomenberg, MD, TEVOGEN BIO's CSO. tinyurl.com/2kc4n7jf #tcell #CellTherapy $TVGN
- tinyurl.com/26h2vp75 “I am also highly optimistic about the potential of TVGN 489 to reduce the mortality and morbidity burden of millions of #LongCOVID patients, where little progress has been made in developing treatments for this condition despite significant government
- Tevogen Bio is aware of disinformation being used by individuals with the intent to harm our company’s reputation and stock price. We will continue to monitor and are working with the appropriate authorities to investigate these false claims" communicates the response
- As we prepare to file our most recent quarterly financials, I want to highlight that Tevogen Bio has the funding it needs to sustain its operations and continue executing our strategy. We remain attentive to enhancing shareholder value, which is always top of mind for our team as
- Our patented ExacTcell technology harness one of nature’s own approaches to eradicating cancer and disease: the cytotoxic or killer T cell. $TVGN #affordable #accessible #celltherapy #biotech
00:00 - #ICYMI We recently announced positive results from our POC #clinicaltrial of #TVGN489, our lead product for the treatment of acute high-risk #COVID19. Read more about how our precision #tcell technology is helping deliver future solutions in care: tinyurl.com/2ueypvbz









